Mettler-Toledo International, INYSE: MTD
Health Care · Life Sciences Tools & Services
$1,150.03
+1.81%
Vol: 126K
Research Digest
Thursday, June 18, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Mettler-Toledo shares fall 2.24% to $1,050.77 after brief 4.2% rebound; analysts cut PTsMixed▶
Mettler-Toledo fell 2.24% on May 19, 2026 to $1,050.77 after a 4.2% rebound to $1,074.84 on May 18, with shares down ~22% over the past month despite a Q1 beat (adjusted EPS $8.91 +9%, revenue $947M, raised FY guidance). Analysts cut PTs sharply: JPMorgan to $1,200 from $1,413, Baird to $1,194 from $1,445, citing organic revenue growth concerns and inflation pressures. The stock is testing what analysts call a historical price floor; Buy ratings remain with median PT ~$1,445 implying significant upside. Company presented at BofA Securities 2026 Healthcare Conference on May 13. Risk: the disconnect between operational beat and price-target cuts suggests skepticism on demand recovery.
May 20Mettler-Toledo revises 2026 executive equity mix; Q1 adj. EPS of $8.91 supports raised FY26 outlook.Positive▶
Mettler-Toledo posted Q1 2026 sales up 7% (local currency +3%, +1% ex-acquisitions) with adjusted EPS of $8.91, +9% y/y. Management guides FY26 local-currency sales growth of ~4% and adjusted EPS of $46.30–$46.95, implying ~8–10% growth. At the May 7 annual meeting, shareholders elected nine directors, ratified PwC as auditor and approved executive pay; the Compensation Committee also adopted a 2026 LTI structure of one-third PSUs, NQSOs and RSUs, granted half in May and half in November. The company presented at the BofA Securities 2026 Healthcare Conference on May 13. Tone is modestly positive on solid execution and reaffirmed guidance.
May 19Mettler-Toledo presented at the BofA Securities 2026 Healthcare Conference on May 13, 2026 amid stock weakness and macro stress-test concerns.Mixed▶
On May 13, 2026, Mettler-Toledo presented at the BofA Securities 2026 Healthcare Conference, with management reaffirming the FY26 outlook including local-currency sales growth of ~4% and adjusted EPS of $46.30-$46.95 (8-10% growth). The stock has been under pressure, trading between $1,039.81 and $1,079.69 on May 18, 2026, well below the median analyst target of around $1,445, with several analysts cutting targets after macro jitters. The May 7 compensation-committee decision split 2026 LTI grants into May and November tranches with the CEO target value up ~6.25% over 2025. The Q1 print on May 7 showed sales up 7% reported (3% local currency) and adjusted EPS up 9% to $8.91, with strength in the Industrial segment and improving China demand. The risk is renewed macro/tariff-driven order softness, which Trefis flagged in a May 13 historical drawdown stress test.
May 18Mettler-Toledo shares slid to ~$1,033 on May 18 as JPMorgan cut PT to $1,200 from $1,413 and Baird slashed to $1,194, despite Q1 EPS of $8.91 beating estimates.Mixed▶
Multiple analysts cut price targets in May 2026: JPMorgan to $1,200 (from $1,413), Baird to $1,194 (from $1,445), and Citi to $1,550 (from $1,700). MTD traded $1,028-$1,057 on May 18, around $1,033. The cuts come despite Q1 2026 sales rising 7% to $947M and adjusted EPS up 9% to $8.91, with the company raising full-year adjusted EPS guidance to $46.30-$46.95 (8-10% growth). On May 7, the Compensation Committee approved a bifurcated 2026 equity grant structure (half May, half November). MTD presented at the BofA Healthcare Conference on May 13.
May 15Mettler-Toledo extended a 5-day losing streak to -23% through May 14 (~$6.1B market cap lost) despite a Q1 beat with $947M revenue and $8.91 adjusted EPS up 9%.Negative▶
Mettler-Toledo International suffered a 5-day losing streak through May 14, 2026, with cumulative losses of approximately 23% wiping out about $6.1 billion in market cap (now near $21B). The sell-off followed Q1 2026 results reported May 7, where revenue rose 7% to $947M (3% local-currency, 1% organic) and adjusted EPS climbed 9% to $8.91 versus $8.19 prior year. Despite raising full-year EPS guidance, analyst PT cuts pressured the stock. MTD presented at BofA Securities 2026 Healthcare Conference on May 13. On May 7 the comp committee approved 2026 long-term incentive awards (CEO LTI +6.25%, other NEOs +12.5%). Risk: cautious life-sciences and China demand could keep volume growth muted; valuation reset still underway.
May 14Mettler-Toledo shares fell 4.1% on May 11 to $1078.53 despite Q1 beat as Morgan Stanley and Citi cut price targetsMixed▶
Mettler-Toledo reported Q1 2026 sales of $947.1M (+7%) and adjusted EPS of $8.91 (+9% YoY), raising full-year EPS guidance to $46.30-$46.95 with Q2 sales seen up ~3%. Despite the beat, shares fell 4.1% on May 11 to $1,078.53 as Morgan Stanley cut PT to $1,275 from $1,475 and Citi reduced to $1,550 from $1,700. The May 7 annual meeting approved all directors, PwC as auditor, and executive comp; the Compensation Committee restructured 2026 LTI awards into a bifurcated May/November grant. The company presented at BofA Healthcare Conference May 13. Risk: lab equipment demand decel and China exposure pressuring valuation multiple.
May 13Mettler-Toledo presenting at BofA Healthcare Conference May 13 after May 7 Q1 beat (EPS $8.91 vs $8.70) but Q2 guidance of $10.70-$10.85 fell below consensus $10.96.Mixed▶
Mettler-Toledo is presenting at the BofA Securities 2026 Healthcare Conference on May 13, 2026. The May 7 Q1 2026 results beat with $8.91 EPS vs $8.70 consensus and revenue of $947.13M vs $943.14M. Management maintained ~4% full-year local currency sales growth and raised adjusted EPS guidance to $46.30-$46.95. However, Q2 EPS guidance of $10.70-$10.85 came in below the Street's $10.96 estimate. Tariffs reduced Q1 operating profit by ~4% and gross margin by 90 bps. Citigroup reduced its price objective from $1,700 to $1,550, maintaining a Buy rating.
May 12Mettler-Toledo shares fell 4.1% to $1,078.53 on May 11 as analysts trimmed price targets despite Q1 2026 beat (adj EPS $8.91 vs $8.70 est, revenue $947.1M) and raised FY26 EPS guidance to $46.30-$46.95.Mixed▶
Mettler-Toledo reported Q1 2026 reported sales up 7% to $947.1M and adjusted EPS of $8.91 (+9% YoY), beating consensus. The company raised full-year 2026 adjusted EPS guidance to $46.30-$46.95 (8-10% growth) and guided Q2 adjusted EPS to $10.70-$10.85. Despite the beat, shares dropped 4.1% on May 11 with analysts including Citigroup cutting price targets (to $1,550 from $1,700). The stock has been pressured by post-earnings reactions and concerns about local currency growth of only 3%. MTD will present at the BofA Healthcare Conference on May 13. Risk: muted underlying organic growth suggests weak end-market demand.
May 11Mettler-Toledo gaps down 15% despite Q1 beat as tariffs cut operating profit 4% and Citi cuts targetNegative▶
Mettler-Toledo reported Q1 2026 adjusted EPS of $8.91 (vs $8.70 expected) and revenue of $947.1 million (vs $943.1M expected), up 7.2% YoY. Despite the beat, the stock gapped down 15.34% before market open Friday, falling from $1,319 to $1,193, after tariffs reduced Q1 operating profit by ~4% and gross margin by 90 basis points, and war-driven higher energy costs caused customer delays and softer demand in European chemicals. Management raised FY 2026 EPS guidance to $46.30-$46.95 vs $46.51 consensus, with Q2 EPS guidance of $10.70-$10.85. Citigroup lowered its price target from $1,700 to $1,550, keeping Buy. The company will present at BofA Healthcare Conference on May 13.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $466.53 | +1.05% | +2.8% | 17.1x | 0.87 | $172.7B |
| DHRDANAHER | $177.74 | -0.01% | +3.5% | 19.1x | 0.83 | $125.4B |
| AAGILENT | $127.36 | +2.44% | +11.7% | 19.2x | 1.26 | $35.9B |
| WATWATERS | $356.50 | -0.14% | +4.1% | 21.6x | 1.20 | $34.9B |
| IQVIQVIA | $168.20 | -1.45% | -2.2% | 11.8x | 1.22 | $28.0B |
| MTDMETTLER | $1,150.03 | +1.81% | +5.7% | 22.3x | 1.26 | $23.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.